MannKind—In the Eclipse of Greatness
Aug 25, 2021 13:41:03 GMT -5
via mobile
afrezzamiracle, sportsrancho, and 32 more like this
Post by mango on Aug 25, 2021 13:41:03 GMT -5
MannKind—In the Eclipse of Greatness
Heretofore the talk went two ways: MannKind is doomed and facing Chapter 11 bankruptcy, and MannKind has managed to make enormous progress in the face of extreme adversity and on its way to achieving its goals. Well, we now know who was right and to no surprise to me it was the hopeful Longs.
Insurmountable as it may have once seemed, MannKind has now managed to achieve something that very few can or ever will—overcome all odds in the face of extreme adversity and despair, and rise up on top, creating a path never before imaginable or attainable. MannKind is now in the eclipse of greatness.
Victory has now emerged out from the fires of what was once viewed as insurmountable defeat. When I first joined the MannKind story in late 2016, Al Mann had already passed and Sanofi had terminated the partnership with MannKind. Despite the company being in an extremely bad position, the overwhelming despair amongst investors, and the negativity that permeated from article writers, analysts, forum bashers and etc., I was immediately captivated by the Al Mann story and what MannKind represented and meant to him. Looking back, I got in at one of the worst, yet best times. It’s been an honor to experience the death and rebirth of this company with all of you.
What we are seeing unfold today is a brand new MannKind. A new future. A future that has clear direction on a path to greatness. The old saying, “It’s a long and hard road that leads to the heights of greatness,” certainly is manifesting in the MannKind story. When I reflect back on the last 5 years I realize they have been absolutely remarkable.
The tide has turned with Afrezza acceptance—converting a once staunch critic to now a happy Afrezza User. This particular person is a well known diabetes blogger, author and contributor with much influence. We are seeing every week new people discovering the remarkable freedom from diabetes that Afrezza enables a person to achieve. With time, I truly believe Afrezza will become a cornerstone in diabetes medicine, and recognized for the revolutionary medical advancement that it is.
MannKind’s pipeline has changed from a full spectrum of diseases and conditions to a narrow, clear defined path of targeting rare lung diseases and endocrine conditions. This suits MannKind well, and early evidence is showing us that the future is endless in these domains as MannKind still holds the most advanced and revolutionary dry powder technology and inhalation devices. There is so many exciting developments taking place, and it’s very exciting to experience it with other investors.
I’ll close this blog post with a list of company developments—a list so great and long it seems impossible considering the dire circumstances we were facing just a few years prior. This year will go down as being perhaps the most important year in MannKind’s history. We will see that Al Mann’s dream becomes a reality.
• MNKD Partners w/ NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI
• Tyvaso DPI FDA approval OCTOBER this year
• >100 new MannKind jobs being added to Danbury, CT facility
• Afrezza Peds Phase 3 this year
• Clofazimine Phase 1 this year
• Royalties from Thyquidity Co-Promote w/ Vertice Pharma starts NOW
• MannKind and Thirona Bio Join Forces to Develop Inhaled Therapy for Fibrotic Lung Diseases
• BluHale Pro Launch this year
• Afrezza European Union filing this year—NO additional clinical trials required!
• Afrezza filing in Canada this year
• Afrezza Australia approval this year
• $100M+ in annual royalties from partner $UTHR for Tyvaso DPI
• >$300M in cash—enough to get us to cash flow break even
• Cannabis partner Receptor Life Sciences Phase 1 incoming
• Afrezza India Clinical Trial starts this year
• New Afrezza scientific publications this year
• New Medicare coverage for Afrezza Users obtaining CGMs
For life repays
what you put in
—Al Mann
Heretofore the talk went two ways: MannKind is doomed and facing Chapter 11 bankruptcy, and MannKind has managed to make enormous progress in the face of extreme adversity and on its way to achieving its goals. Well, we now know who was right and to no surprise to me it was the hopeful Longs.
Insurmountable as it may have once seemed, MannKind has now managed to achieve something that very few can or ever will—overcome all odds in the face of extreme adversity and despair, and rise up on top, creating a path never before imaginable or attainable. MannKind is now in the eclipse of greatness.
Victory has now emerged out from the fires of what was once viewed as insurmountable defeat. When I first joined the MannKind story in late 2016, Al Mann had already passed and Sanofi had terminated the partnership with MannKind. Despite the company being in an extremely bad position, the overwhelming despair amongst investors, and the negativity that permeated from article writers, analysts, forum bashers and etc., I was immediately captivated by the Al Mann story and what MannKind represented and meant to him. Looking back, I got in at one of the worst, yet best times. It’s been an honor to experience the death and rebirth of this company with all of you.
What we are seeing unfold today is a brand new MannKind. A new future. A future that has clear direction on a path to greatness. The old saying, “It’s a long and hard road that leads to the heights of greatness,” certainly is manifesting in the MannKind story. When I reflect back on the last 5 years I realize they have been absolutely remarkable.
The tide has turned with Afrezza acceptance—converting a once staunch critic to now a happy Afrezza User. This particular person is a well known diabetes blogger, author and contributor with much influence. We are seeing every week new people discovering the remarkable freedom from diabetes that Afrezza enables a person to achieve. With time, I truly believe Afrezza will become a cornerstone in diabetes medicine, and recognized for the revolutionary medical advancement that it is.
MannKind’s pipeline has changed from a full spectrum of diseases and conditions to a narrow, clear defined path of targeting rare lung diseases and endocrine conditions. This suits MannKind well, and early evidence is showing us that the future is endless in these domains as MannKind still holds the most advanced and revolutionary dry powder technology and inhalation devices. There is so many exciting developments taking place, and it’s very exciting to experience it with other investors.
I’ll close this blog post with a list of company developments—a list so great and long it seems impossible considering the dire circumstances we were facing just a few years prior. This year will go down as being perhaps the most important year in MannKind’s history. We will see that Al Mann’s dream becomes a reality.
• MNKD Partners w/ NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI
• Tyvaso DPI FDA approval OCTOBER this year
• >100 new MannKind jobs being added to Danbury, CT facility
• Afrezza Peds Phase 3 this year
• Clofazimine Phase 1 this year
• Royalties from Thyquidity Co-Promote w/ Vertice Pharma starts NOW
• MannKind and Thirona Bio Join Forces to Develop Inhaled Therapy for Fibrotic Lung Diseases
• BluHale Pro Launch this year
• Afrezza European Union filing this year—NO additional clinical trials required!
• Afrezza filing in Canada this year
• Afrezza Australia approval this year
• $100M+ in annual royalties from partner $UTHR for Tyvaso DPI
• >$300M in cash—enough to get us to cash flow break even
• Cannabis partner Receptor Life Sciences Phase 1 incoming
• Afrezza India Clinical Trial starts this year
• New Afrezza scientific publications this year
• New Medicare coverage for Afrezza Users obtaining CGMs
For life repays
what you put in
—Al Mann
